Tokyo - Delayed Quote JPY

MatsukiyoCocokara & Co. (3088.T)

2,888.50
+7.50
+(0.26%)
At close: 3:30:00 PM GMT+9
Loading Chart for 3088.T
  • Previous Close 2,881.00
  • Open 2,912.50
  • Bid 2,881.50 x --
  • Ask 2,889.00 x --
  • Day's Range 2,868.50 - 2,913.00
  • 52 Week Range 2,022.00 - 2,991.50
  • Volume 1,599,400
  • Avg. Volume 1,628,112
  • Market Cap (intraday) 1.166T
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 21.61
  • EPS (TTM) 133.68
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield 46.00 (1.60%)
  • Ex-Dividend Date Sep 29, 2025
  • 1y Target Est 2,876.67

MatsukiyoCocokara & Co. operates and manages a chain of drug stores and health insurance prescription pharmacies in Japan. The company is involved in the franchising of its stores. MatsukiyoCocokara & Co. was founded in 1932 and is based in Tokyo, Japan.

www.matsukiyococokara.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 3088.T

View More

Performance Overview: 3088.T

Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

3088.T
26.42%
Nikkei 225 (^N225)
6.51%

1-Year Return

3088.T
26.02%
Nikkei 225 (^N225)
4.23%

3-Year Return

3088.T
92.09%
Nikkei 225 (^N225)
39.49%

5-Year Return

3088.T
134.23%
Nikkei 225 (^N225)
81.48%

Compare To: 3088.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3088.T

View More

Valuation Measures

Annual
As of 5/20/2025
  • Market Cap

    1.16T

  • Enterprise Value

    1.07T

  • Trailing P/E

    21.53

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.11

  • Price/Book (mrq)

    2.23

  • Enterprise Value/Revenue

    1.01

  • Enterprise Value/EBITDA

    10.04

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.15%

  • Return on Assets (ttm)

    7.14%

  • Return on Equity (ttm)

    10.61%

  • Revenue (ttm)

    1.06T

  • Net Income Avi to Common (ttm)

    54.68B

  • Diluted EPS (ttm)

    133.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    111.75B

  • Total Debt/Equity (mrq)

    0.42%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 3088.T

View More

Company Insights: 3088.T

Research Reports: 3088.T

View More

People Also Watch